Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Bayer and J&J subsidiary Janssen Pharmaceuticals decided to end the phase 3 NAVIGATE ESUS study of Xarelto after they got some bad news – the anticoagulant was no more effective than aspirin in preventing stroke and systemic embolism, and came with a much higher risk of uncontrollable bleeding.
The disappointing results came at a decidedly bad time for Bayer.
Last year, Bayer was flying high on $3.4 billion annual sales of Xarelto, and told analysts to expect the drug’s sales to peak at more than $5.3 billion a year.
But when the trial was stopped for lack of efficacy, Bayer was quick to promise that the setback would not affect its sales forecasts for Xarelto.
To compound matters, Bayer has been trying to play financial catch up with rival Bristol-Myers Squibb (BMS), whose novel oral anticoagulant Eliquis currently holds a commanding lead in sales over Xarelto.
Despite the fact that sales of Xarelto were up 18.6 percent in the second quarter of 2017 over Q2 of 2016, the sales of Eliquis increased 51 percent to nearly $1.2 billion, and Bayer could be in danger of failing to reach peak sales forecasts of $5 billion.
Another blockbuster blood thinner, Pradaxa, is holding firmly in third place with $1.5 in sales last year.
The bleeding risk connected with Xarelto is well documented, and Bayer and J&J are facing more than 18,000 lawsuits over bleeding injuries in state and federal courts.
Portola is working on AndexXa, a bleeding-reversal agent for Xarelto, but the process stalled last year when the company received a letter from the U.S. Food and Drug Administration citing manufacturing problems and other issues.
To address the FDA’s concerns, Portola took out $50 million in loans from partners BMS and Pfizer, and in August, Portola announced that the FDA had accepted its resubmitted application for approval.
A decision is expected by February 2018.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
According to the FDA, 20-ounce packages of “King Kullen Broccoli Cutlets with Bread Crumbs and Parmesan” have been recalled by New Haven, Connecticut-based Gracie’s Kitchen due to the potential presence of undeclared sesame and wheat. Individuals who live with allergies to either allergen are advised
The FDA is warning consumers of a Class I recall of Boston Scientific’s Obsidio Comformable Embolic because the device has been shown to present a risk for increased bowel ischemia when used for lower GI (gastrointestinal) bleeding, or acute colonic bleeding. As a pre-mixed embolic
Animal nutrition business Cargill has announced a recall of Nutrena Country Feeds Meat bird 22% Crumble (RV) because the product after the product was found to be missing Vitamin D, according to the FDA. Growing birds who consume a diet lacking in the vitamin can